Evaluating Blinatumomab for the Treatment of Relapsed/Refractory ALL: Design, Development, and Place in Therapy

Although adults with B-cell acute lymphoblastic leukemia (B-ALL) achieve high complete remission (CR) rates following treatment with intensive multi-agent chemotherapy regimens, up to two-thirds of these patients eventually relapse. Unfortunately, adults with relapsed or refractory (R/R) B-ALL have...

Descripción completa

Detalles Bibliográficos
Autores principales: Sigmund, Audrey M, Sahasrabudhe, Kieran D, Bhatnagar, Bhavana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648528/
https://www.ncbi.nlm.nih.gov/pubmed/33173373
http://dx.doi.org/10.2147/BLCTT.S223894

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648528/
https://www.ncbi.nlm.nih.gov/pubmed/33173373
http://dx.doi.org/10.2147/BLCTT.S223894

Ejemplares similares